Dermatologic Therapy最新文献

{"title":"Apremilast in Patients Difficult to Treat: A Multicentric Real-Life Long-Term Experience","authors":"Emanuele Trovato,&nbsp;Eugenio Capalbo,&nbsp;Alessandra Cartocci,&nbsp;Gionata Buggiani,&nbsp;Aldo Cuccia,&nbsp;Alberto Ghilardi,&nbsp;Salvatore Panduri,&nbsp;Imma Savarese,&nbsp;Serena Guiducci,&nbsp;Francesca Prignano","doi":"10.1155/2023/9775738","DOIUrl":"10.1155/2023/9775738","url":null,"abstract":"<div>\u0000 <p>Psoriasis is an inflammatory disease nowadays considered not only as a cutaneous but also as a systemic disease. Systemic therapy plays a crucial role in the management of psoriasis. Apremilast is an inhibitor of phosphodiesterase-4 (PDE4), indicated in the treatment of moderate-to-severe psoriasis. Here, we report a multicentric case series of patients treated with apremilast with resolution of skin manifestations and maintenance of clinical response for a minimum of 2 years. By inhibiting PDE4, apremilast acts as a ubiquitous intracellular enzyme, whose active form degrades adenosine cyclic intracellular monophosphate (cAMP) into AMP. The increase in cAMP determines a decrease in proinflammatory cytokines such as TNF-a, IL-17, IL-23, and upregulation of IL-10 with an anti-inflammatory action. Considering the growing incidence of comorbidities in the world population and in particular the strict correlation in patients with psoriasis, it is important to identify therapeutic options able to avoid a negative impact on patients with both conditions. The aim of this work is to highlight the utility of this molecule in the long-term management of these patients. Moreover, these case series further underline the high safety profile and manageability of this small molecule.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/9775738","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136105987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study","authors":"Luca Mastorino,&nbsp;Valentina Celoria,&nbsp;Nicole Macagno,&nbsp;Caterina Cariti,&nbsp;Sara Susca,&nbsp;Niccolò Siliquini,&nbsp;Michela Ortoncelli,&nbsp;Elena Stroppiana,&nbsp;Anna Verrone,&nbsp;Lorenza Burzi,&nbsp;Pietro Quaglino,&nbsp;Simone Ribero,&nbsp;Paolo Dapavo","doi":"10.1155/2023/1793535","DOIUrl":"10.1155/2023/1793535","url":null,"abstract":"<div>\u0000 <p><i>Introduction</i>. Psoriasis of the scalp, genital areas, and palms and soles represents a treatment challenge in clinical practice. Randomized clinical trials and real-life studies investigating the efficacy of biological drugs in these sites are scarce. The present is a descriptive retrospective real-life study with the aim to evaluate the efficacy and safety of brodalumab in these difficult-to-treat areas. <i>Materials and Methods</i>. 158 psoriatic patients with scalp involvement, 69 with genital involvement, and 54 with palmoplantar involvement being treated with brodalumab were assessed at weeks 16, 28, and 48 using PSSI (Psoriasis Scalp Severity Index), sPGA-G (Physician Global Assessment of Genitalia), and ppPASI (Palmoplantar Psoriasis Area and Severity Index). <i>Results</i>. The achievement of relative PSSIs (75%, 90%, and 100%) was already observed in week 16. 86% achieved PSSI75, 80% PSSI90, and 75% PSSI100. The sPGA-g 0/1 was achieved by 83% of patients at week 16 and 100% at week 24 and 48. At week 16 ppPASI75, 90, and 100 were all reached by 76.9% of patients; at week 24, 84.6% of patients reached all relative ppPASI. <i>Conclusions</i>. Brodalumab proved to be effective and safe in the treatment of scalp, genital, and palmoplantar regions.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/1793535","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136376630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenchymal Stem Cells-Derived Extracellular Vesicles as Nanotherapeutics: An Application for Skin Wound Healing","authors":"Xin-Yu Ben,&nbsp;Meng-Si Tian,&nbsp;Hui-Hui Zheng,&nbsp;Ya-Ru Wang,&nbsp;Tian-Wei Cui,&nbsp;Rui Ren,&nbsp;Xi-Nan Yi,&nbsp;Qi-Fu Li","doi":"10.1155/2023/7916795","DOIUrl":"10.1155/2023/7916795","url":null,"abstract":"<div>\u0000 <p>The skin covers the entire outer part of the body as the largest organ. Because this organ is directly exposed to microbial, thermal, mechanical, and chemical damage, several factors may injure it, including acute trauma, chronic wounds, or even surgical procedures. Mesenchymal stem cells- (MSCs-) derived extracellular vesicles (EVs) can inhibit the inflammatory response in the early stage of skin wound healing, promote angiogenesis and the proliferation and migration of epithelial cells, and regulate collagen synthesis and inhibit scar proliferation in the later stage. While MSCs-EVs have broad prospects for clinical applications, it will still be a long way to seamless healing. In this brief review, we focus on the role of MSCs-EV in skin wound repair, therapeutic effects, and potential mechanisms of MSCs-EV in reducing scar formation. It is concluded that MSCs-EV can reduce scar formation in skin wound repair by interfering with multiple inflammatory factors, regulating fibroblast proliferation, and expressing type I and type III collagens at different phases.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/7916795","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135510911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Superficial Radiotherapy (SRT-100) as an Effective Noninvasive Treatment for Pyogenic Granuloma: Case Report and Literature Review","authors":"Ying-Hua Song,&nbsp;Dan Chen,&nbsp;Shuang Deng,&nbsp;Wei-Na Cai,&nbsp;Liang Zhang","doi":"10.1155/2023/8829881","DOIUrl":"10.1155/2023/8829881","url":null,"abstract":"<div>\u0000 <p><i>Introduction</i>. Pyogenic granuloma (PG) is a common condition characterized by the appearance of a small raspberry-like vascular growth that may appear on any part of the skin. PG usually occurs secondary to acute or chronic trauma. The primary treatment for PG is noninvasive therapy. In refractory cases, surgical resection is an alternative. Superficial radiation therapy system (SRT-100) is a new technology that uses low-energy radiotherapy to treat nonmelanoma skin cancers. SRT may also be used for the treatment of patients with PG who are unwilling to undergo surgery. <i>Case Presentation</i>. A 27-year-old woman presented with a recurrent neoplasm in the middle finger of the left hand after surgical resection. She refused to undergo reoperation or other aggressive options such as electrocautery or liquid nitrogen cryotherapy, so we prescribed only superficial radiotherapy (SRT-100) alone, with a total dose of 14 Gy in four fractions. <i>Conclusion</i>. The neoplasm gradually flattened after treatment with 14 Gy in four fractions and disappeared completely 3 months after completion of treatment.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/8829881","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135511806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage Migration Inhibitory Factor and Gene Polymorphism (rs755622G>C) in Unstable Vitiligo Patients","authors":"Hassan M. Ibrahim,&nbsp;Mohammed H. Hassan,&nbsp;Moustafa A. El-Taieb,&nbsp;Essam Nada,&nbsp;Soheir Abdel-Hamid,&nbsp;Ali Younis,&nbsp;Mahmoud Ali,&nbsp;Eisa M. Hegazy","doi":"10.1155/2023/9937187","DOIUrl":"10.1155/2023/9937187","url":null,"abstract":"<div>\u0000 <p>Vitiligo pathogenesis is related to the macrophage migration inhibitory factor (MIF) protein. This study aimed to assess the lesional MIF levels and gene polymorphisms (rs755622G&gt;C) in patients with vitiligo. To assess the consequences of combining narrow-band ultraviolet B with oral minipulse prednisolone as opposed to a combination with oral methotrexate on MIF levels in vitiligo patients, 50 unstable vitiligo patients and 50 controls were randomly chosen for comparison. MIF levels in skin homogenates and MIF (rs755622G&gt;C) single nucleotide polymorphisms were assessed using the ELISA and the polymerase chain reaction restriction fragment length polymorphism (RFLP-PCR) techniques. We found significantly higher lesional MIF levels, a higher frequency of both (GC) and (CC) genotypes, and a significantly more frequent mutant allele (C) in patients than in controls. In addition, there was a significantly lower frequency of the allele (C) among patients who exhibited moderate to marked therapeutic improvement than among those who showed minimal to mild improvement. In conclusion, tissue MIF and gene polymorphisms were associated with vitiligo. In addition, oral corticosteroids, narrow-band ultraviolet B, methotrexate-targeted tissue MIF, and gene polymorphisms can improve unstable vitiligo.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/9937187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135618831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Efficacy and Safety of Topical Nanoliposomal Amphotericin B 0.4% Gel as a Potential Treatment for Onychomycosis: An Interventional Pilot Clinical Study","authors":"Alireza Firooz,&nbsp;Shayan Zamani,&nbsp;Aliasghar Ghadrei,&nbsp;Azin Ayatollahi,&nbsp;Pegah Tamimi,&nbsp;Ali Khamesipour,&nbsp;Mahmoodreza Jafari,&nbsp;Mahsa Fattahi","doi":"10.1155/2023/9955124","DOIUrl":"10.1155/2023/9955124","url":null,"abstract":"<div>\u0000 <p>Onychomycosis is a frequent fungal nail disease that is hard to treat and, in most cases, needs long-term therapy with oral agents. Traditionally, oral agents are favored over topical agents, but it should not be overlooked that they come with broad adverse effects and concomitant drug interactions, which can be unsuitable for many individuals. Therefore, alternative approaches need to be addressed by the medical team for numerous cases. On the other hand, local administration of antimicrobials can come as advantageous because of having a more selective site of activity, avoiding off-target systemic adverse effects, and rapid administration at the site of infection. In this study, we are evaluating a new topical delivery method of amphotericin B. To investigate the efficacy and safety of topical nanoliposomal amphotericin B 0.4% as a possible therapeutic option, this pilot, single-group, before-after clinical study was conducted on 15 onychomycosis patients. The evaluation was processed during 36 weeks of follow-up and on three endpoints of week 12, week 24, and week 36, for both clinical and mycological responses. Three patients were excluded; of the remaining 12, 50% showed a complete cure, 16.66% had an effective clinical response, 16.66% had a partial clinical response, and 16.66% showed no response at week 12. Mycological cure was calculated as 50% at week 12. At week 24, our measurements were calculated as 91.66% for complete cure, 8.33% for no response, and 91.66% for mycological cure. One patient reported nail plate detachment at week 2 but continued the topical application; follow-up between weeks 2 and 24 showed a complete cure and regrowth of healthy nails. No other adverse effects were detected. Overall, our study suggests that topical nanoliposomal amphotericin B 0.4% is an effective treatment, which is accessible, affordable, and user-friendly, has minimum adverse effects, and could be regarded as an alternative treatment for those ineligible for systemic therapy. This trial is registered with IRCT20150101020514N18.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/9955124","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136078842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy, Safety, and Recurrence Rate of Diphenylcyclopropenone Topical Immunotherapy for Alopecia Areata: A Systemic Review and Meta-Analysis","authors":"Jiaping Zhu,&nbsp;Rui Qiao,&nbsp;Yufen Li,&nbsp;Xuemei Lan,&nbsp;Xiangdong Gong,&nbsp;Yiqun Jiang","doi":"10.1155/2023/6073889","DOIUrl":"10.1155/2023/6073889","url":null,"abstract":"<div>\u0000 <p><i>Background and Objective</i>. Diphenylcyclopropenone topical immunotherapy is widely used in the treatment of alopecia areata. However, previous studies have shown significant differences in its efficacy. We conducted this systemic review and meta-analysis to investigate the efficacy, safety, and recurrence rate of diphenylcyclopropenone topical immunotherapy for alopecia areata. <i>Methods</i>. Literatures related to diphenylcyclopropenone topical immunotherapy for alopecia areata between January 1st, 2002, and July 2nd, 2022, were searched in the following databases: PubMed, Embase, Cochrane Library, Sinomed, WanFang Data, and Chinese Medical Journal Network. <i>Results</i>. This meta-analysis included a total of 40 moderate to high quality studies involving 3,002 patients. The overall rate of any hair regrowth was 69%, and the overall rate of complete hair regrowth was 23%. The rate of any hair regrowth in patients with alopecia totalis or alopecia universalis was 42%, and the rate of any hair regrowth in patients with other types of alopecia areata was 75%. Common side effects were mild contact dermatitis (36%), severe contact dermatitis (31%), regional lymphadenopathy (22%), hyperpigmentation (22%), and hypopigmentation (7%). The recurrence rate was 37%. <i>Conclusion</i>. Diphenylcyclopropenone topical immunotherapy is an effective treatment for various types of alopecia areata, and most of its common side effects are acceptable.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/6073889","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135739027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between LRG1 and Adipokines in Psoriasis","authors":"Keshuai Liu,&nbsp;Lanzhi Li,&nbsp;Yue Li,&nbsp;Xingwu Duan,&nbsp;Hailing Dong,&nbsp;Ziqing You","doi":"10.1155/2023/6689580","DOIUrl":"10.1155/2023/6689580","url":null,"abstract":"<div>\u0000 <p><i>Background and Objective</i>. Patients with psoriasis may exhibit abnormal changes in serum adipokine levels, which are often related to disease severity of the disease. Leucine-rich alpha-2-glycoprotein 1 (LRG1) is an acute-phase inflammatory protein that may be linked to adipokines in psoriasis. In this study, we evaluated the differences in the expression of adipokines and LRG1 between patients with psoriasis and healthy individuals, analyzed the correlation between the expression of LRG1 and adipokines, and explored their relationship with psoriatic lesions. <i>Methods</i>. In this cross-sectional study, patients with psoriasis (<i>n</i> = 54) and healthy controls (<i>n</i> = 26) were enrolled, and their clinical characteristics were recorded. Fasting venous blood samples were collected from each participant. The serum concentrations of leptin, resistin, adiponectin, and LRG1 in each sample were measured using the enzyme-linked immunosorbent assay. <i>Results</i>. The study included 54 patients with psoriasis vulgaris and 26 healthy controls. The serum levels of LRG1, leptin, and resistin were significantly higher in patients with psoriasis than in healthy controls. Conversely, adiponectin levels were significantly lower in patients with psoriasis. The study showed that LRG1 expression was positively correlated with leptin and resistin expression but negatively correlated with adiponectin expression. Interestingly, only leptin, resistin, and LRG1 expression showed a linear correlation with the Psoriasis Area and Severity Index (PASI). When we categorized patients with psoriasis based on their LRG1 levels, we observed that the group with high LRG1 levels showed a higher PASI. <i>Conclusions</i>. We observed a significant correlation between LRG1 and adipokine expression in patients with psoriasis. In addition, the expression levels of LRG1, leptin, and resistin were observed to be correlated with the severity of psoriasis. We believe that the occurrence and development of psoriasis are collectively influenced by LRG1 and leptin/resistin expression.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/6689580","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135697462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Dystrophic Epidermolysis Bullosa Pruriginosa: A Systematic Review of Clinical Outcomes after Initiation of Dupilumab Therapy","authors":"Christopher J. Issa,&nbsp;Aubrey C. Hong,&nbsp;Peter A. Lio","doi":"10.1155/2023/3863357","DOIUrl":"10.1155/2023/3863357","url":null,"abstract":"<div>\u0000 <p>Dystrophic epidermolysis bullosa pruriginosa (DEB-Pr), a highly pruritic subtype of dystrophic epidermolysis bullosa (DEB), can substantially impact patients’ quality of life due to symptom severity. This review features 10 patients diagnosed with DEB-Pr and a history of insufficient symptom relief following anti-inflammatory treatment. However, after initiation of dupilumab therapy, these patients exhibited marked clinical improvements in pruritic and cutaneous symptoms. Interestingly, one study showed an increase in type VII collagen following dupilumab therapy. These findings highlight the influence of T helper 2 (Th2)-mediated immunity in the pathogenesis of itch in DEB-Pr and dupilumab’s potential in the treatment of refractory pruritus.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/3863357","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135193960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Statistical Analysis of Vitiligo Exacerbation after COVID-19 Vaccination in China","authors":"Tao Wang,&nbsp;Yaojun Wang,&nbsp;Yue Zhang,&nbsp;Jiaoni Chi,&nbsp;Qiang Li","doi":"10.1155/2023/4711236","DOIUrl":"10.1155/2023/4711236","url":null,"abstract":"<div>\u0000 <p>At present, COVID-19 vaccination is an effective method to stop the spread of the epidemic and reduce disease severity and mortality. It has been reported that COVID-19 vaccine can activate several autoimmune diseases. However, whether it can affect development of vitiligo remains elusive. In this study, we aimed to evaluate the possible risk factors of vitiligo disease activity or recurrence after COVID-19 vaccination. We recruited 383 vitiligo patients, of whom 126 were not vaccinated and 257 had received the COVID-19 vaccine. Vitiligo disease activity (VIDA) score was used to analyze key risk factors of vitiligo in patients who underwent COVID-19 vaccination. Multivariate logistic regression models were used to explore the risk factors associated with VIDA. Compared with patients without history of undergoing vaccination, the VIDA score of vaccinated patients increased significantly (3(2, 4) vs. 3(2, 3) scores, <i>P</i>  &lt;  0.01). Logistic regression analysis identified COVID-19 vaccination (odds ratio (OR): 3.040, 95% confidence interval (CI): 1.649–5.603) as an independent risk factor for VIDA. The data showed that COVID-19 vaccination aggravated the development of vitiligo, which is a key risk factor for recurrence.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/4711236","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135814718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}